Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiquimod Gel in Actinic Keratosis
NCT01583816Phase 2Completed
- Sponsor
- Spirig Pharma
- Start
- May 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of resiquimod in actinic keratosis (AK) (5 arms), sponsored by Spirig Pharma. Primary endpoint: Number of patients with complete clinical clearance in the treated area. Started May 2012; status: completed.
02
Drugs
resiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01583816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01583816.